SPOTLIGHT: India focuses on biosimilars
India sees a big future for itself in biogenerics. Wockhardt, Dr Reddy's Lab, Biocon, Sun Pharma, Shanta Biotech, Panacea Biotech and Ranbaxy Lab are all initiating programs to develop biosimilars in anticipating of U.S. approval of a new regulatory pathway--at some point. Exactly what that point is, though, remains a mystery. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
